Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not include a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback